메뉴 건너뛰기




Volumn 17, Issue 1, 2016, Pages

Cognitive behavioral therapy program for cannabis use cessation in first-episode psychosis patients: Study protocol for a randomized controlled trial

Author keywords

Cannabis; First episode psychosis; Psychological treatment

Indexed keywords

ARTICLE; ASSESSMENT OF HUMANS; CANNABIS ADDICTION; CANNABIS USE CESSATION; CANNABIS USE PROBLEMS IDENTIFICATION TEST; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PROTOCOL; COGNITIVE BEHAVIORAL THERAPY; CONTROLLED STUDY; DRUG WITHDRAWAL; EXPERIMENTAL DESIGN; FOLLOW UP; FUNCTIONING ASSESSMENT SHORT TEST; HAMILTON ANXIETY SCALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MEDICATION COMPLIANCE; MORISKY MEDICATION ADHERENCE SCALE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOEDUCATION; PSYCHOSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCALE TO ASSESS UNAWARENESS IN MENTAL DISORDERS; SINGLE BLIND PROCEDURE; SOCIAL PSYCHOLOGY; STUDY DESIGN; TREATMENT DURATION; ADOLESCENT; ADULT; COGNITIVE THERAPY; METHODOLOGY; PROCEDURES; PSYCHOLOGY; YOUNG ADULT;

EID: 84979654236     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-016-1507-x     Document Type: Article
Times cited : (6)

References (62)
  • 5
    • 84874830696 scopus 로고    scopus 로고
    • Cannabis use in patients at clinical high risk of psychosis: impact on prodromal symptoms and transition to psychosis
    • van der Meer FJ, Velthorst E, Meijer CJ, Machielsen MWJ, de Haan L. Cannabis use in patients at clinical high risk of psychosis: impact on prodromal symptoms and transition to psychosis. Curr Pharm Des. 2012;18:5036-44.
    • (2012) Curr Pharm Des. , vol.18 , pp. 5036-5044
    • Meer, F.J.1    Velthorst, E.2    Meijer, C.J.3    Machielsen, M.W.J.4    Haan, L.5
  • 7
    • 84891811498 scopus 로고    scopus 로고
    • Cannabis use and first episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation
    • Stone JM, Fisher HL, Major B, Chisholm B, Woolley J, Lawrence J, et al. Cannabis use and first episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation. Psychol Med. 2014;44:499-506.
    • (2014) Psychol Med. , vol.44 , pp. 499-506
    • Stone, J.M.1    Fisher, H.L.2    Major, B.3    Chisholm, B.4    Woolley, J.5    Lawrence, J.6
  • 8
    • 84874400244 scopus 로고    scopus 로고
    • The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the Psychosis Incident Cohort Outcome Study (PICOS)
    • Tosato S, Lasalvia A, Bonetto C, Mazzoncini R, Cristofalo D, De Santi K, PICOS-VENETO GROUP, et al. The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the Psychosis Incident Cohort Outcome Study (PICOS). J Psychiatric Res. 2013;47:438-44.
    • (2013) J Psychiatric Res. , vol.47 , pp. 438-444
    • Tosato, S.1    Lasalvia, A.2    Bonetto, C.3    Mazzoncini, R.4    Cristofalo, D.5    Santi, K.6
  • 10
    • 77950453195 scopus 로고    scopus 로고
    • Age of onset of cannabis use is associated with age of onset of high-risk symptoms for psychosis
    • Dragt S, Nieman DH, Becker HE, van de Fliert R, Dingemans PM, de Haan L, et al. Age of onset of cannabis use is associated with age of onset of high-risk symptoms for psychosis. Can J Psychiatry. 2010;55:165-71.
    • (2010) Can J Psychiatry. , vol.55 , pp. 165-171
    • Dragt, S.1    Nieman, D.H.2    Becker, H.E.3    Fliert, R.4    Dingemans, P.M.5    Haan, L.6
  • 11
    • 83555176239 scopus 로고    scopus 로고
    • Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis
    • Dragt S, Nieman DH, Schultze-Lutter F, van der Meer F, Becker H, de Haan L, EPOS group, et al. Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. Acta Psychiatr Scand. 2012;125:45-53.
    • (2012) Acta Psychiatr Scand. , vol.125 , pp. 45-53
    • Dragt, S.1    Nieman, D.H.2    Schultze-Lutter, F.3    Meer, F.4    Becker, H.5    Haan, L.6
  • 12
    • 84895814739 scopus 로고    scopus 로고
    • Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users
    • Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014;40:1509-17.
    • (2014) Schizophr Bull. , vol.40 , pp. 1509-1517
    • Forti, M.1    Sallis, H.2    Allegri, F.3    Trotta, A.4    Ferraro, L.5    Stilo, S.A.6
  • 13
    • 34447106643 scopus 로고    scopus 로고
    • Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use
    • Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden BM, Kranaster L, et al. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res. 2007;94:29-36.
    • (2007) Schizophr Res. , vol.94 , pp. 29-36
    • Leweke, F.M.1    Giuffrida, A.2    Koethe, D.3    Schreiber, D.4    Nolden, B.M.5    Kranaster, L.6
  • 14
    • 39149145495 scopus 로고    scopus 로고
    • Cannabis use and brain structural alterations in first episode schizophrenia-a region of interest, voxel based morphometric study
    • Bangalore SS, Prasad KM, Montrose DM, Goradia DD, Diwadkar VA, Keshavan MS. Cannabis use and brain structural alterations in first episode schizophrenia-a region of interest, voxel based morphometric study. Schizophr Res. 2008;99:1-6.
    • (2008) Schizophr Res. , vol.99 , pp. 1-6
    • Bangalore, S.S.1    Prasad, K.M.2    Montrose, D.M.3    Goradia, D.D.4    Diwadkar, V.A.5    Keshavan, M.S.6
  • 15
    • 79955473886 scopus 로고    scopus 로고
    • Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia
    • Ho BC, Wassink TH, Ziebell S, Andreasen NC. Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophr Res. 2011;128:66-75.
    • (2011) Schizophr Res. , vol.128 , pp. 66-75
    • Ho, B.C.1    Wassink, T.H.2    Ziebell, S.3    Andreasen, N.C.4
  • 17
    • 46849111394 scopus 로고    scopus 로고
    • Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia
    • Eggan SM, Hashimoto T, Lewis DA. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry. 2008;65:772-84.
    • (2008) Arch Gen Psychiatry. , vol.65 , pp. 772-784
    • Eggan, S.M.1    Hashimoto, T.2    Lewis, D.A.3
  • 20
    • 8444242207 scopus 로고    scopus 로고
    • Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms
    • Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology. 2004;29:2108-14.
    • (2004) Neuropsychopharmacology. , vol.29 , pp. 2108-2114
    • Giuffrida, A.1    Leweke, F.M.2    Gerth, C.W.3    Schreiber, D.4    Koethe, D.5    Faulhaber, J.6
  • 21
    • 79955442545 scopus 로고    scopus 로고
    • Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use
    • González-Pinto A, Alberich S, Barbeito S, Gutierrez M, Vega P, Ibáñez B, et al. Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull. 2011;37:631-39.
    • (2011) Schizophr Bull. , vol.37 , pp. 631-639
    • González-Pinto, A.1    Alberich, S.2    Barbeito, S.3    Gutierrez, M.4    Vega, P.5    Ibáñez, B.6
  • 22
    • 84889854747 scopus 로고    scopus 로고
    • Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial
    • Clausen L, Hjorthoj CR, Thorup A, Jeppesen P, Petersen L, Bertelsen M, et al. Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial. Psychol Med. 2014;44:117-26.
    • (2014) Psychol Med. , vol.44 , pp. 117-126
    • Clausen, L.1    Hjorthoj, C.R.2    Thorup, A.3    Jeppesen, P.4    Petersen, L.5    Bertelsen, M.6
  • 23
    • 84865998027 scopus 로고    scopus 로고
    • Medication adherence mediates the impact of sustained cannabis use on symptom levels in first-episode psychosis
    • Faridi K, Joober R, Malla A. Medication adherence mediates the impact of sustained cannabis use on symptom levels in first-episode psychosis. Schizoph Res. 2012;141:78-82.
    • (2012) Schizoph Res. , vol.141 , pp. 78-82
    • Faridi, K.1    Joober, R.2    Malla, A.3
  • 24
    • 84860833892 scopus 로고    scopus 로고
    • Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study
    • van Dijk D, Koeter MW, Hijman R, Kahn RS, van den Brink W. Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study. Schizoph Res. 2012;137:50-7.
    • (2012) Schizoph Res. , vol.137 , pp. 50-57
    • Dijk, D.1    Koeter, M.W.2    Hijman, R.3    Kahn, R.S.4    Brink, W.5
  • 25
    • 84878954045 scopus 로고    scopus 로고
    • Characterizing the longitudinal patterns of substance use among individuals diagnosed with serious mental illness after psychiatric hospitalization
    • Bahorik AL, Newhill CE, Eack SM. Characterizing the longitudinal patterns of substance use among individuals diagnosed with serious mental illness after psychiatric hospitalization. Addiction. 2013;108:1259-69.
    • (2013) Addiction. , vol.108 , pp. 1259-1269
    • Bahorik, A.L.1    Newhill, C.E.2    Eack, S.M.3
  • 26
    • 84861796547 scopus 로고    scopus 로고
    • Continued cannabis use and outcome in first-episode psychosis: data from a randomized, open-label, controlled trial
    • Faber G, Smid HG, Van Gool AR, Wunderink L, van den Bosch RJ, Wiersma D. Continued cannabis use and outcome in first-episode psychosis: data from a randomized, open-label, controlled trial. J Clin Psychiatry. 2012;73:632-38.
    • (2012) J Clin Psychiatry. , vol.73 , pp. 632-638
    • Faber, G.1    Smid, H.G.2    Gool, A.R.3    Wunderink, L.4    Bosch, R.J.5    Wiersma, D.6
  • 27
    • 84928882689 scopus 로고    scopus 로고
    • Social functioning trajectories of young first-episode psychosis patients with and without cannabis misuse: A 30-month follow-up study
    • González-Blanch C, Gleeson JF, Koval P, Cotton SM, McGorry PD, Alvarez-Jimenez M. Social functioning trajectories of young first-episode psychosis patients with and without cannabis misuse: A 30-month follow-up study. PLoS ONE. 2015;10(4):e0122404.
    • (2015) PLoS ONE , vol.10 , Issue.4
    • González-Blanch, C.1    Gleeson, J.F.2    Koval, P.3    Cotton, S.M.4    McGorry, P.D.5    Alvarez-Jimenez, M.6
  • 28
    • 22344447728 scopus 로고    scopus 로고
    • The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis
    • Lambert M, Conus P, Lubman DI, Wade D, Yuen H, Moritz S, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand. 2005;112:141-48.
    • (2005) Acta Psychiatr Scand. , vol.112 , pp. 141-148
    • Lambert, M.1    Conus, P.2    Lubman, D.I.3    Wade, D.4    Yuen, H.5    Moritz, S.6
  • 29
    • 84979693615 scopus 로고    scopus 로고
    • Revisión de los tratamientos psicológicos en primeros episodios psicóticos
    • Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad y Política Social Servicio de Evaluación de Tecnologías Sanitarias del País Vasco 2009. Report of the Basque Office for Health Technology Assessment. (OSTEBA) No. 2007/08.
    • Ruiz de Azúa García S, González-Pinto Arrillaga A, Vega Pérez P, Gutíerrez Fraile M, Asua Batarrita J. Revisión de los tratamientos psicológicos en primeros episodios psicóticos. Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad y Política Social Servicio de Evaluación de Tecnologías Sanitarias del País Vasco 2009. Report of the Basque Office for Health Technology Assessment. (OSTEBA) No. 2007/08.
    • Ruiz de Azúa García, S.1    González-Pinto Arrillaga, A.2    Vega Pérez, P.3    Gutíerrez Fraile, M.4    Asua Batarrita, J.5
  • 30
    • 84885046638 scopus 로고    scopus 로고
    • Cognitive behavioral therapy after first episodes psychosis
    • Lecardeur L. Cognitive behavioral therapy after first episodes psychosis. Encephale. 2013;39:115-20.
    • (2013) Encephale. , vol.39 , pp. 115-120
    • Lecardeur, L.1
  • 31
    • 79960774988 scopus 로고    scopus 로고
    • Motivational intervention to reduce cannabis use in young people with psychosis: a randomized controlled trial
    • Bonsack C, Gibellini S, Favrod J, Montagrin Y, Besson J, Bovet P, et al. Motivational intervention to reduce cannabis use in young people with psychosis: a randomized controlled trial. Psychother Psychosom. 2011;80:287-97.
    • (2011) Psychother Psychosom. , vol.80 , pp. 287-297
    • Bonsack, C.1    Gibellini, S.2    Favrod, J.3    Montagrin, Y.4    Besson, J.5    Bovet, P.6
  • 32
    • 33745818603 scopus 로고    scopus 로고
    • Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis
    • Edwards J, Elkins K, Hinton M, Harrigan SM, Donovan K, Athanasopoulos O, et al. Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatr Scand. 2006;114:109-17.
    • (2006) Acta Psychiatr Scand. , vol.114 , pp. 109-117
    • Edwards, J.1    Elkins, K.2    Hinton, M.3    Harrigan, S.M.4    Donovan, K.5    Athanasopoulos, O.6
  • 33
    • 84860586478 scopus 로고    scopus 로고
    • Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trial
    • Hjorthøj CR, Fohlmann A, Larsen AM, Arendt M, Nordentoft M. Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trial. Addiction. 2012a;107:1123-31.
    • (2012) Addiction , vol.107 , pp. 1123-1131
    • Hjorthøj, C.R.1    Fohlmann, A.2    Larsen, A.M.3    Arendt, M.4    Nordentoft, M.5
  • 34
    • 84871938589 scopus 로고    scopus 로고
    • A multi-center, randomized controlled trial of a group psychological intervention for psychosis with comorbid cannabis dependence over the early course of illness
    • Madigan K, Brennan D, Lawlor E, Turner N, Kinsella A, O'Connor JJ, et al. A multi-center, randomized controlled trial of a group psychological intervention for psychosis with comorbid cannabis dependence over the early course of illness. Schizophr Res. 2013;143:138-42.
    • (2013) Schizophr Res. , vol.143 , pp. 138-142
    • Madigan, K.1    Brennan, D.2    Lawlor, E.3    Turner, N.4    Kinsella, A.5    O'Connor, J.J.6
  • 35
    • 84924283350 scopus 로고    scopus 로고
    • A phase-specific psychological therapy for people with problematic cannabis use following a first episode of psychosis: a randomized controlled trial
    • Barrowclough C, Marshall M, Gregg L, Fitzsimmons M, Tomenson B, Warburton J, et al. A phase-specific psychological therapy for people with problematic cannabis use following a first episode of psychosis: a randomized controlled trial. Psychol Med. 2014;44:2749-61.
    • (2014) Psychol Med. , vol.44 , pp. 2749-2761
    • Barrowclough, C.1    Marshall, M.2    Gregg, L.3    Fitzsimmons, M.4    Tomenson, B.5    Warburton, J.6
  • 36
  • 37
    • 0000262577 scopus 로고    scopus 로고
    • EUROP-ASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence
    • Kokkevi A, Hartgers C. EUROP-ASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur Addict Res. 2015;1:208-10.
    • (2015) Eur Addict Res. , vol.1 , pp. 208-210
    • Kokkevi, A.1    Hartgers, C.2
  • 38
    • 4243429844 scopus 로고    scopus 로고
    • Índice europeo de la severidad de la adicción: EuropASI
    • Versión española, Actas de la IV Reunión Interregional de Psiquiatría
    • Bobes J, González MP, Sáiz PA, Bousoño M. Índice europeo de la severidad de la adicción: EuropASI. Versión española, Actas de la IV Reunión Interregional de Psiquiatría. 1996. p. 201-18.
    • (1996) , pp. 201-218
    • Bobes, J.1    González, M.P.2    Sáiz, P.A.3    Bousoño, M.4
  • 39
    • 77949364471 scopus 로고    scopus 로고
    • The Cannabis Use Problems Identification Test (CUPIT): development, reliability, concurrent and predictive validity among adolescents and adults
    • Bashford J, Ross F, Copeland Jan. The Cannabis Use Problems Identification Test (CUPIT): development, reliability, concurrent and predictive validity among adolescents and adults. Addiction. 2010;105:615-25.
    • (2010) Addiction , vol.105 , pp. 615-625
    • Bashford, J.1    Ross, F.2    Jan, C.3
  • 40
    • 1942523532 scopus 로고    scopus 로고
    • Hungarian adaptation of the European Addiction Severity Index
    • Gerevich J, Bacskai E, Rozsa S. Hungarian adaptation of the European Addiction Severity Index. J Subst Use. 2004;9:185-91.
    • (2004) J Subst Use. , vol.9 , pp. 185-191
    • Gerevich, J.1    Bacskai, E.2    Rozsa, S.3
  • 41
    • 41949098135 scopus 로고    scopus 로고
    • The reliability and validity testing of the Hungarian version of the EuropASI
    • Jozsef R, Csilla P, Nauszika MA. The reliability and validity testing of the Hungarian version of the EuropASI. Magyar Psichologiai Szemle. 2002;57:587-603.
    • (2002) Magyar Psichologiai Szemle. , vol.57 , pp. 587-603
    • Jozsef, R.1    Csilla, P.2    Nauszika, M.A.3
  • 42
    • 1942523531 scopus 로고    scopus 로고
    • Introduction of the EuropASI in Norway: clinical and research experiences from a cost-effectiveness study
    • Lauritzen G, Ravndal E. Introduction of the EuropASI in Norway: clinical and research experiences from a cost-effectiveness study. J Subst Use. 2004;9:141-6. 11.
    • (2004) J Subst Use , vol.9 , pp. 141-146
    • Lauritzen, G.1    Ravndal, E.2
  • 43
    • 0033851847 scopus 로고    scopus 로고
    • Anwendung des European Addiction Severity Index (EuropASI) im Rahmen einer ambulanten Behandlung von Drogenabhängigen
    • Weiler D, Vogt M, Kufner H. Anwendung des European Addiction Severity Index (EuropASI) im Rahmen einer ambulanten Behandlung von Drogenabhängigen. Zeistchrift fur Wissenschaft und Praxis. 2000;46:197-208.
    • (2000) Zeistchrift fur Wissenschaft und Praxis. , vol.46 , pp. 197-208
    • Weiler, D.1    Vogt, M.2    Kufner, H.3
  • 44
    • 0033637119 scopus 로고    scopus 로고
    • Reliability and validity of the German version of the European Addiction Severity Index (EuropASI)
    • Scheurich A, Muller MJ, Wetzel H, Anghelescu I, Klawe C, Ruppe A, et al. Reliability and validity of the German version of the European Addiction Severity Index (EuropASI). J Stud Alcohol. 2000;61:916-9.
    • (2000) J Stud Alcohol. , vol.61 , pp. 916-919
    • Scheurich, A.1    Muller, M.J.2    Wetzel, H.3    Anghelescu, I.4    Klawe, C.5    Ruppe, A.6
  • 48
  • 49
    • 0022632510 scopus 로고
    • Concurrent and predictive validity of a self-reported measure of medication adherence
    • Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67-74.
    • (1986) Med Care. , vol.24 , pp. 67-74
    • Morisky, D.E.1    Green, L.W.2    Levine, D.M.3
  • 50
    • 0026482157 scopus 로고
    • Descriptive study of patient compliance in pharmacologic antihypertensive treatment and validation of the Morisky and Green test [in Spanish]
    • Val A, Amorós G, Martínez P, Fernández ML, León M. Descriptive study of patient compliance in pharmacologic antihypertensive treatment and validation of the Morisky and Green test [in Spanish]. Aten Primaria. 1992;10:767-70.
    • (1992) Aten Primaria. , vol.10 , pp. 767-770
    • Val, A.1    Amorós, G.2    Martínez, P.3    Fernández, M.L.4    León, M.5
  • 51
    • 0023606101 scopus 로고
    • The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
    • Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizoph Bull. 1987;13:261-76.
    • (1987) Schizoph Bull. , vol.13 , pp. 261-276
    • Kay, S.R.1    Fiszbein, A.2    Opler, L.A.3
  • 52
    • 0001230724 scopus 로고
    • Validation of Positive and Negative Symptom Scale (PANSS) in a sample of Spanish schizophrenic patients
    • Peralta-Martin V, Cuesta-Zorita MJ. Validation of Positive and Negative Symptom Scale (PANSS) in a sample of Spanish schizophrenic patients. Actas Luso-Esp Neurol, Psiquiatr Cienc Afines. 1994;22:171-77.
    • (1994) Actas Luso-Esp Neurol, Psiquiatr Cienc Afines. , vol.22 , pp. 171-177
    • Peralta-Martin, V.1    Cuesta-Zorita, M.J.2
  • 53
    • 0014186152 scopus 로고
    • Development of a rating scale for primary depressive illness
    • Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-96.
    • (1967) Br J Soc Clin Psychol. , vol.6 , pp. 278-296
    • Hamilton, M.1
  • 54
    • 0022745925 scopus 로고
    • Validación de la versión castellana de la escala de Hamilton para la depresión
    • Ramos-Brieva JCA. Validación de la versión castellana de la escala de Hamilton para la depresión. Actas Luso-Esp Neurol, Psiquiatr Cienc Afines. 1986;14:324-34.
    • (1986) Actas Luso-Esp Neurol, Psiquiatr Cienc Afines. , vol.14 , pp. 324-334
    • Ramos-Brieva, J.C.A.1
  • 55
  • 57
    • 51549099524 scopus 로고
    • The assessment of anxiety states by rating
    • Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-5.
    • (1959) Br J Med Psychol. , vol.32 , pp. 50-55
    • Hamilton, M.1
  • 58
    • 0037070878 scopus 로고    scopus 로고
    • Validación de las versiones en español de la Montgomery-Asberg Depression Rating Scale y la Hamilton Anxiety Rating Scale para la evaluación de la depresión y de la ansiedad
    • Lobo A, Chamorro L. Validación de las versiones en español de la Montgomery-Asberg Depression Rating Scale y la Hamilton Anxiety Rating Scale para la evaluación de la depresión y de la ansiedad. Med Clin (Barc). 2002;118:493-9.
    • (2002) Med Clin (Barc) , vol.118 , pp. 493-499
    • Lobo, A.1    Chamorro, L.2
  • 62
    • 0002591676 scopus 로고
    • Toward a comprehensive model of change
    • In: Miller WR, Heather N, editors. New York: Plenum Press;
    • Prochaska JO, DiClemente CC. Toward a comprehensive model of change. In: Miller WR, Heather N, editors. Addictive behaviors: processes of change. New York: Plenum Press; 1986. p. 3-28.
    • (1986) Addictive behaviors: processes of change , pp. 3-28
    • Prochaska, J.O.1    DiClemente, C.C.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.